Positive initial clinical data from Phase 1 trial with ALN-PCSsc
2 September 2015 | By Victoria White
In the Phase 1 study, subcutaneous administration of ALN-PCSsc resulted in an up to 83% lowering of LDL-C, with an up to 64 ± 5% mean maximum reduction, comparable to published results for anti-PCSK9 MAbs...